ArticleThoracic cancer2021

Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation.

Tadashi Nishimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.